Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03325790 · ClinicalTrials.gov registry record · Phase 2
SPI-1005 for the Treatment of Patients With Meniere's Disease
A Phase 2 study, sponsored by Sound Pharmaceuticals, Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT03325790 is a Phase 2 study that has completed, run by Sound Pharmaceuticals, Incorporated. The registered enrollment target is 149 participants.
The verdict
NCT03325790, a Phase 2 study, has completed, sponsored by Sound Pharmaceuticals, Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
Interventions
- OTHER Placebo
- DRUG 200mg SPI-1005 BID
- DRUG 400mg SPI-1005 BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2019-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03325790
The ClinicalTrials.gov registry entry for NCT03325790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sound Pharmaceuticals, Incorporated, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03325790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03325790 about?
NCT03325790 is a clinical study titled "SPI-1005 for the Treatment of Patients With Meniere's Disease". This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
What is the current status of trial NCT03325790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2017-09-28. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03325790?
The interventions under investigation include: Placebo (OTHER), 200mg SPI-1005 BID (DRUG), 400mg SPI-1005 BID (DRUG).
Who is sponsoring clinical trial NCT03325790?
This trial is sponsored by Sound Pharmaceuticals, Incorporated, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.